时至今日，安保的许多产品都是自主知识产权产品，被广泛用于诊断和观察过程、呼吸支持、院外心肺复苏、基础和高级复苏训练、创伤固定以及预防感染等。在安保，质量是第一位的，因此，无论产品还是工艺都通过ISO9001/ EN46001等质量认证体系标准，成品标上了CE的标志，并完全符合美国食品与药品管理局（FDA）有关质量标准的“最优制造过程”（GMP）要求。

安保产品通过分支机构和代理走向全球，无论是医院、医疗急救服务中心、还是专业与非专业救助人员和机构、乃至一般开业人员、还有军队和企业。出口约占销售的98%。一旦锁定区域，安保提供优质独特的产品，致力于取得有利的市场地位。我们公司将不断创新，开发核心能力，为市场提供新产品，以满足当今社会的需求。1992年，安保国际公司在哥本哈根证券交易所开盘上市。1995年，对AB Germa的收购进一步巩固了固定类产品。1999年，安保开始运作二○○二战略，目标于三年内，通过生产外包、或收购类似产品或公司的举措来实现营业额和利润翻三番。2000年对Medicotest的收购是安保向实行二○○二战略迈出的关键性的一步，此项并购使得安保成为了住院和门诊产品市场的佼佼者。 集团总部设在丹麦哥本哈根市郊的Ballerup，中国和马来西亚都拥有生产基地。安保公司现有员工1,600人，其中丹麦300人，国外1,300人。2000年11月01日安保总公司收购了巨贸有限公司，由此正式进入中国， 成立了安保（厦门）塑胶工业有限公司，秉承安保对质量孜孜不倦的追求，成为安保在亚洲的主要生产基地，包括生命维护设备和训练设备。由CEO Lars Marcher提出的GPS4战略方针（2009-2013）将更加着眼于中国的发展。目前，公司坐落于厦门象屿保税区内，投资所有资产1000万美金，拥有一幢5层楼的厂房，其中包括行政办公区、注塑车间、加工车间、仓库等，我们还拥有一个10万级的洁净车间，所有产品均输送销往欧美各大洲，目前员工有700多人。

Today Ambu's products, many of which are patented, are used for diagnostic and monitoring procedures, respiratory support, external cardiopulmonary resuscitation, basic and advanced resuscitation training, immobilisation and protection against infections. In Ambu we assign high priority to quality, and our products and processes are certified to ISO9001/ EN46001, our products bear the CE mark and we conform to FDA requirements for GMP. Ambu is represented worldwide by subsidiaries and distributors to hospitals, emergency medical services (EMS), professional and non-professional rescuers, relief organizations, general practitioners, armed forces and industries. Exports account for approx. 98% of sales. Ambu offers unique products of a high quality, and the Group has a favourable market position in the areas chosen as its focus areas. And we will continue to innovate and develop our core competencies in order to bring to the market new products that serve the needs and demands of the day. In 1992 Ambu International A/S was quoted on the Copenhagen Stock exchange. In 1995, with the acquisition of AB Germa, Ambu strengthened its range of immobilization products. In 1999, Ambu launched Strategy 2002 with the objective of attaining a trebling in turnover and profit in three years through an outsourcing of production and the acquisition of products or companies relevant to Ambu. With the acquisition in 2000 of Medicotest, Ambu took an important step toward the fulfillment of strategy 2002. This integration makes Ambu one of the leading concerns within the hospital and pre-hospital market. The Group is headquartered in Ballerup outside Copenhagen, Denmark, and has production facilities in Ballerup and Olstykke in Denmark, and in China and Malaysia. Ambu has approximately 1,600 employees, of whom 300 work in Denmark and 1,300 abroad. Dynasty was acquisted by Ambu A/S on 01-Nov-2000. Ambu Ltd. establishment is the milestone of Ambu entering into China. Adhering the Quality ethic, Ambu Ltd. became the main production site in Asia, including Life-care Device & Training Device producing. Moverover, GPS4 2009~2013 strategy which is developed and promoted by CEO Lars Marcher is more focusing on China development. Now, Ambu Ltd. locates in F.T.Z (Free Tax Zone) in Xiamen island, invested more than 10 Million USD and owns a five floors buiding, including Administration Area, Injection Workshop, Assembly Workshop, 100K level Clean-Room, Warehous, etc. All produces are exported to Europe and US and other continents markets. There are roughly 700 employees in Ambu Ltd.